Back to search
Verified
Government
Health
Ryplle ID RYP-0647Last checked Oct 28, 2026

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

National Institutes of Health

Funding range
$0 – $7M
Application window
Opens: Not listed
Closes: January 29, 2027
Applications Status:Upcoming
Location
National
Apply on funder's site

Source & verification

Original funding source
www.grants.gov
Last checked
October 28, 2026
Last reviewed by Ryplle
Not yet recorded

Source checks may be automated. Review dates reflect a recorded staff review. Confirm current requirements with the funder.

Eligibility at a glance

Listed applicant types
Student, Nonprofit, Business
Geographic eligibility
National
Matching funds
Not specified — check with the funder
Major exclusions
Not specified — check with the funder

Listed types are not a determination of eligibility. The funder’s full requirements take precedence.

Full eligibility requirements

Eligible applicants: Public and State controlled institutions of higher education; County governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Independent school districts; City or township governments; Native American tribal governments (Federally recognized); Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); For profit organizations other than small businesses; Special district governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Public housing authorities/Indian housing authorities; State governments.

About this grant

The purpose of this notice of funding opportunity (NOFO) is to support a consortium of Translational Centers using Microphysiological Systems (MPS) for Infectious Diseases (TCMID). Recent efforts in the MPS fields are moving towards validation and regulatory use but have not focused upon models studying infectious diseases and testing of medical interventions. The NIH and FDA have recently issued guidance and established initiatives for enhancing use of New Approach Methodologies (NAMs) in research and product development. This includes in vitro systems that allow scientists to model human disease and capture human variability and patient-specific characteristics that will accelerate safer treatments for patients while reducing costs and sparing use of laboratory animals. To meet this need, the Centers will refine well validated human tissue models studying infectious diseases to a level consistent with regulatory qualifications that will promote their adoption for use by product developers, supporting regulatory acceptance.

Contact information